POS-321 TRANSLATING THE FINDINGS OF THE ROXADUSTAT NDD GLOBAL PHASE 3 PROGRAM INTO COST OFFSETS FROM A CANADIAN HEALTHCARE PERSPECTIVE
J. Schneider, S. Davies, A. Howarth and 7 more
Kidney International Reports · 2021
doi:10.1016/j.ekir.2021.03.337 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Chronic kidney disease (CKD) is a costly public health issue, with an estimated prevalence of 13.4% globally. Anemia is a common complication associated with CKD resulting in reduced health-related quality of life and high healthcare costs. The objective of this analysis was to estimate the direct medical care cost offsets of investigational agent roxadustat for the treatment of anemia in patients with non-dialysis dependent (NDD) CKD from a Canadian healthcare perspective.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.